NK-92细胞联合靶向Her2基因的siRNA治疗卵巢癌的体外及动物实验

程志祥; 朱园园; 周颖; 凌斌; 祝怀平

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

NK-92细胞联合靶向Her2基因的siRNA治疗卵巢癌的体外及动物实验

程志祥 , 朱园园 , 周颖 , 凌斌 , 祝怀平

文章导航 > 蚌埠医学院学报 > 2014, 39 > 8: (1008-1011)

引用本文:

Citation:

NK-92细胞联合靶向Her2基因的siRNA治疗卵巢癌的体外及动物实验

1. 安徽医科大学附属合肥医院, 安徽省合肥市第二人民医院检验科, 230001;
2. 安徽医科大学附属安徽省立医院分子医学重点实验室, 安徽合肥 230001

作者简介: 程志祥（1979-）男，硕士研究生，主管检验师.

中图分类号: R737.31;R342.2

Experiment of NK-92 cells combined with siRNA targeting Her2 gene in the treatment of ovarian cancer in vivo and in vitro

1. Department of Clinical Laboratory, The Affiliated Hefei Hospital of Anhui Medical University, Hefei Anhui 230001;
2. Key Laboratory of Molecular Medicine, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei Anhui 230001, China
CLC number: R737.31;R342.2

摘要: 目的：探讨NK-92细胞对抑制Her2基因表达的卵巢癌细胞株SKOV-3细胞在体外及体内的杀伤活性。方法：靶向Her2的siRNA转染SKOV-3，筛选得到能稳定抑制Her2基因表达的细胞株SKOV-3/siRNA，并通过RT-PCR和免疫组织化学方法检测Her2基因抑制效果。应用LDH法检测NK-92细胞对SKOV-3、SKOV-3/siRNA的杀伤活性。将SKOV-3、SKOV-3/siRNA细胞接种到裸鼠皮下检测荷瘤情况，并比较NK-92细胞在各组治疗效果。结果：建立了稳定抑制Her2基因表达的细胞株SKOV-3/siRNA，Her2基因表达受到较强抑制。NK-92在效靶比1：20时对SKOV-3、SKOV-3/siRNA细胞杀伤率分别为（21.1±6.8）%和（45.5±8.9）%，差异有统计学意义（P<0.01）。接种SKOV-3/siRNA细胞实验组各时间点瘤体积均明显小于SKOV-3对照组（P<0.05~P<0.01）。SKOV3/siRNA+ NK-92治疗组肿瘤质量均小于其他各组（P<0.05~P<0.01）。结论：NK-92细胞联合靶向Her2基因的siRNA可以抑制卵巢癌细胞株SKOV-3在体外和体内增殖，有望成为卵巢肿瘤治疗的新途径。
- 卵巢肿瘤 /
- 杀伤细胞, 天然 /
- Her2基因
Abstract: Objective: To explore the inhibition effects of NK-92 cells on the Her-2 gene expression in SKOV-3 cells in vitro and in vivo.Methods: The SKOV-3/siRNA cell line with persistent silencing the Her2 gene expression were established by the siRNA targeting Her2 gene transfecting into SKOV-3 cell line.The inhibition effects on Her2 gene mRNA expression were detected by RT-PCR and immunohistochemistry.The killing activity of NK-92 cells to SKOV-3 and SKOV-3/siRNA was detected by LDH.The tumor growth in the nude mice inoculated with SKOV-3 and SKOV-3/siRNA subcutaneously was observed.The effects of NK-92 cells on ovarian cancer in all cases were compared.Results: The SKOV-3/siRNA cell line with persistent silencing the Her2 gene expression was established,the Her2 gene expression was strong inhibited.The killing rates of NK-92 cells to SKOV-3 and SKOV-3/siRNA were(21.1±6.8)% and(45.5±8.9)% at 1：20 of the target ratio,respectively(P<0.01).The tumor volume in mice inoculated with SKOV-3/siRN cells was significantly less than that in mice inoculated with ASKOV-3(P<0.05 to P<0.01),The tumor quality in mice treated with SKOV-3/siRN combined with NK-92 cells were significantly less than that in other mice(P<0.05 to P<0.01).Conclusions: NK-92 cells combined with siRNA targeting Her2 gene can inhibit the proliferation of the ovarian cancer cell line SKOV-3 in vitro and in vivo,which may become a new approach of ovarian cancer therapy.
- ovarian neoplasm /
- killing cells,nature /
- Her 2 gene

[1]	Slamon DJ, Godolphin W, Jones LA, et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science, 1989, 244(4905):707-712.
[2]	Cheng JC, Qiu X, Chang HM, et al.HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells[J].Biochem Biophys Res Commun, 2013, 434(1):81-86.
[3]	Arai S, Meagher R, Swearingen M, et al.Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma:a phase Ⅰ trial[J].Cytotherapy, 2008, 10(6):625-632.
[4]	Tam YK, Maki G, Miyagawa B, et al.Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy[J].Hum Gene Ther, 1999, 10(8):1359-1373.
[5]	Uchino K, Ochiya T, Takeshita F.RNAi Therapeutics and applications of microRNAs in cancer treatment[J].Jpn J Clin Oncol, 2013, 43(6):596-607.
[6]	周颖, 凌斌, 高婷, 等.siRNA靶向Her-2逆转录病毒载体构建及其在SKOV3中的表达[J].肿瘤防治研究, 2007(4):277-280.
[7]	程志祥, 周颖, 朱园园, 等.靶向Her2基因SiRNA对人卵巢癌细胞株SKOV-3 顺铂敏感性的影响[J].安徽医科大学学报, 2007, 42(4):374-378.
[8]	Chay WY, Chew SH, Ong WS, et al.HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer[J].PLoS One, 2013, 8(4):e61565.
[9]	Yu M, Shi W, Zhang J, et al.Influence of reverse signaling via membrane TNF-α on cytotoxicity of NK92 cells[J].Eur J Cell Biol, 2009, 88(3):181-191.
[10]	Liu XC, Liang H, Tian Z, et al.Proteomic analysis of human NK-92 cells after NK cell-mediated cytotoxicity against K562 cells[J].Biochemistry(Mosc), 2007, 72(7):716-727.
[11]	许恬怡, 凌斌, 陈纲, 等.放射线照射后NK-92 细胞对人宫颈癌细胞体外杀伤活性的研究[J].肿瘤防治研究, 2005, 32(6):336-338.

[1]	缪晨婷 , 钱静 , 朱璟 . IL-33及其受体ST2对人卵巢癌ES-2细胞增殖、凋亡、迁移和侵袭的影响. 蚌埠医学院学报, 2020, 45(12): 1606-1610. doi: 10.13898/j.cnki.issn.1000-2200.2020.12.004
[2]	俞岚 , 汪万英 , 王朝夫 , 姚敏 . 卵巢肿瘤MMP-2、MMP-9及TIMP-2和细菌L型检测的意义. 蚌埠医学院学报, 2005, 30(3): 198-201.
[3]	游牧 , 刘文 , 饶圣宏 , 徐振山 , 宋礼华 . 应用组织芯片技术检测卵巢癌组织中基质金属蛋白酶-2和p185^HER-2/neu的表达及其临床意义. 蚌埠医学院学报, 2011, 36(5): 448-451.
[4]	何玉 , 晋茂生 , 杜丹丽 , 王才智 . RASSF 1A基因在卵巢癌组织及腹腔冲洗液中甲基化的研究. 蚌埠医学院学报, 2011, 36(1): 35-37,41.
[5]	衡燕春 , 马珊珊 , 马玲 . 调节性B细胞在卵巢癌病人外周血中表达及其临床意义. 蚌埠医学院学报, 2021, 46(6): 767-770, 774. doi: 10.13898/j.cnki.issn.1000-2200.2021.06.015
[6]	秦安敏 , 司应明 , 付盈盈 , 刘思丽 . 二氢杨梅素诱导人卵巢癌HO-8910细胞凋亡及机制研究. 蚌埠医学院学报, 2021, 46(10): 1340-1345. doi: 10.13898/j.cnki.issn.1000-2200.2021.10.004
[7]	王玲玲 , 席玉玲 , 凌斌 , 赵卫东 , 承泽农 . 凋亡抑制基因Livin在卵巢上皮性癌组织中的表达及其与PTEN的相关性研究. 蚌埠医学院学报, 2011, 36(3): 223-226.
[8]	郭冰沁 , 俞岚 . 卵巢癌MMP-2、MMP-9和VEGF-C表达与其生物学行为的关系. 蚌埠医学院学报, 2007, 32(4): 381-383,506.
[9]	相媛媛 , 张莘 , 林仲秋 , 周晖 , 徐国才 , 张丙忠 . 雷帕霉素联合顺铂对卵巢癌SKOV3细胞株凋亡和周期的影响. 蚌埠医学院学报, 2013, 37(10): 1249-1252.
[10]	朱静 , 宋悦 . 低剂量LBH589通过PI3K/AKT途径诱导对上皮性卵巢癌细胞凋亡作用机制研究. 蚌埠医学院学报, 2019, 44(6): 708-711. doi: 10.13898/j.cnki.issn.1000-2200.2019.06.003
[11]	刘静波 , 郭晨旭 , 马玲 . 人参皂苷Rg1联合奈达铂通过Hedgehog通路抑制卵巢癌细胞OVCAR-3的增殖及机制探究. 蚌埠医学院学报, 2020, 45(4): 442-446. doi: 10.13898/j.cnki.issn.1000-2200.2020.04.006
[12]	彭程 , 李敏 , 周颖 , 赵卫东 , 冯定庆 , 凌斌 . 白细胞介素-6在上皮性卵巢癌中的表达及其意义. 蚌埠医学院学报, 2009, 34(2): 117-119.
[13]	吴晓莉 , 张林杰 , 许健 . IL-18真核表达载体的构建及其在HO-8910细胞株的表达. 蚌埠医学院学报, 2008, 33(2): 144-146.
[14]	王捷文 , 赵卫东 , 承泽农 . Ki-67、VEGF在卵巢交界性肿瘤中的表达及其意义. 蚌埠医学院学报, 2011, 36(10): 1071-1074.
[15]	谷文文 , 杜丹丽 . 肿瘤标志物在卵巢癌早期诊断的研究进展. 蚌埠医学院学报, 2012, 36(3): 367-369.
[16]	王立群 , 赵卫东 , 席玉玲 , 焦雪娟 , 承泽农 . p53和survivin在交界性上皮性卵巢肿瘤中的表达及其临床意义. 蚌埠医学院学报, 2011, 36(10): 1078-1080,1083.
[17]	万敏 . 腹腔镜手术治疗卵巢良性肿瘤79例临床观察. 蚌埠医学院学报, 2007, 32(5): 539-540.
[18]	陈秀艳 . 妊娠合并卵巢肿瘤及瘤样病变39例诊治分析. 蚌埠医学院学报, 2009, 34(9): 821-822.
[19]	陈军莹 , 姚德生 . microRNA在卵巢癌中的研究进展. 蚌埠医学院学报, 2012, 36(1): 119-122.
[20]	张小鹏 , 王晓玉 . 整合素与卵巢癌转移的相关性研究进展. 蚌埠医学院学报, 2011, 36(2): 205-208.

点击查看大图

计量

文章访问数: 3211
HTML全文浏览量: 221
PDF下载量: 7
被引次数: 0

NK-92细胞联合靶向Her2基因的siRNA治疗卵巢癌的体外及动物实验

作者简介: 程志祥（1979-）男，硕士研究生，主管检验师.

1. 安徽医科大学附属合肥医院, 安徽省合肥市第二人民医院检验科, 230001;
2. 安徽医科大学附属安徽省立医院分子医学重点实验室, 安徽合肥 230001

收稿日期: 2013-08-14

关键词:

摘要: 目的：探讨NK-92细胞对抑制Her2基因表达的卵巢癌细胞株SKOV-3细胞在体外及体内的杀伤活性。方法：靶向Her2的siRNA转染SKOV-3，筛选得到能稳定抑制Her2基因表达的细胞株SKOV-3/siRNA，并通过RT-PCR和免疫组织化学方法检测Her2基因抑制效果。应用LDH法检测NK-92细胞对SKOV-3、SKOV-3/siRNA的杀伤活性。将SKOV-3、SKOV-3/siRNA细胞接种到裸鼠皮下检测荷瘤情况，并比较NK-92细胞在各组治疗效果。结果：建立了稳定抑制Her2基因表达的细胞株SKOV-3/siRNA，Her2基因表达受到较强抑制。NK-92在效靶比1：20时对SKOV-3、SKOV-3/siRNA细胞杀伤率分别为（21.1±6.8）%和（45.5±8.9）%，差异有统计学意义（P<0.01）。接种SKOV-3/siRNA细胞实验组各时间点瘤体积均明显小于SKOV-3对照组（P<0.05~P<0.01）。SKOV3/siRNA+ NK-92治疗组肿瘤质量均小于其他各组（P<0.05~P<0.01）。结论：NK-92细胞联合靶向Her2基因的siRNA可以抑制卵巢癌细胞株SKOV-3在体外和体内增殖，有望成为卵巢肿瘤治疗的新途径。

English Abstract

Experiment of NK-92 cells combined with siRNA targeting Her2 gene in the treatment of ovarian cancer in vivo and in vitro

1. Department of Clinical Laboratory, The Affiliated Hefei Hospital of Anhui Medical University, Hefei Anhui 230001;
2. Key Laboratory of Molecular Medicine, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei Anhui 230001, China

Received Date: 2013-08-14

Abstract: Objective: To explore the inhibition effects of NK-92 cells on the Her-2 gene expression in SKOV-3 cells in vitro and in vivo.Methods: The SKOV-3/siRNA cell line with persistent silencing the Her2 gene expression were established by the siRNA targeting Her2 gene transfecting into SKOV-3 cell line.The inhibition effects on Her2 gene mRNA expression were detected by RT-PCR and immunohistochemistry.The killing activity of NK-92 cells to SKOV-3 and SKOV-3/siRNA was detected by LDH.The tumor growth in the nude mice inoculated with SKOV-3 and SKOV-3/siRNA subcutaneously was observed.The effects of NK-92 cells on ovarian cancer in all cases were compared.Results: The SKOV-3/siRNA cell line with persistent silencing the Her2 gene expression was established,the Her2 gene expression was strong inhibited.The killing rates of NK-92 cells to SKOV-3 and SKOV-3/siRNA were(21.1±6.8)% and(45.5±8.9)% at 1：20 of the target ratio,respectively(P<0.01).The tumor volume in mice inoculated with SKOV-3/siRN cells was significantly less than that in mice inoculated with ASKOV-3(P<0.05 to P<0.01),The tumor quality in mice treated with SKOV-3/siRN combined with NK-92 cells were significantly less than that in other mice(P<0.05 to P<0.01).Conclusions: NK-92 cells combined with siRNA targeting Her2 gene can inhibit the proliferation of the ovarian cancer cell line SKOV-3 in vitro and in vivo,which may become a new approach of ovarian cancer therapy.